Low molecular weight heparin (enoxaparin) versus dextran in the prevention of early occlusion following arterial bypass surgery distal to the groin

K. Logason*, D. Bergqvist

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)

Abstract

Aim: To compare the effect of perioperative dextran and low molecular weight heparin on early graft patency after femorodistal bypass surgery. Design: Prospective randomised multicentre study. Patients and methods: Three hundred and fourteen patients were randomised to dextran 70 or the low molecular weight heparin enoxaparin during and after femorodistal bypass surgery. Patency was evaluated at days 1, 5-7, 30 and 90. Results: There was no difference in patency at any time point between the two regimens, the crude 90 days patency being 88 and 83%, respectively. There were significantly more patients with heart failure in the dextran group (12.8 vs. 0.7%), with other side effects being equally distributed. Conclusion: Dextran 70 and the low molecular weight heparin enoxaparin have the same effect on 90 days femorodistal graft patency, but care must be taken using the dextran to patients with a potential heart insufficiency.

Original languageEnglish
Pages (from-to)261-265
Number of pages5
JournalEuropean Journal of Vascular and Endovascular Surgery
Volume21
Issue number3
DOIs
Publication statusPublished - 2001

Bibliographical note

Funding Information:
Swedish Medical Research Council 00759, grant from Rhône-Poulenc Rorer (now Aventis) to Swedvasc.

Other keywords

  • Dextran
  • Femorodistal bypass occlusion
  • Low molecular weight heparin

Fingerprint

Dive into the research topics of 'Low molecular weight heparin (enoxaparin) versus dextran in the prevention of early occlusion following arterial bypass surgery distal to the groin'. Together they form a unique fingerprint.

Cite this